Clinical Trials in Portland

Showing 1321-1340 of 10,048 trials

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

NCT04848337

Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.

Prostate Cancer MetastaticNeuroendocrine Tumors

University of Michigan Rogel Cancer Center45 participantsStarted May 2021

Duarte, California, United States • Atlanta, Georgia, United States • Ann Arbor, Michigan, United States +2 more locations

RECRUITINGNA< 1 mile

Sleep and Circadian Mechanisms in Hypertension

NCT05184933

This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).

HypertensionCardiovascular DiseasesCardiovascular Risk Factors+2 more

Oregon Health and Science University32 participantsStarted Aug 2022

Portland, Oregon, United States

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Sleep and Circadian Mechanisms in Hypertension

Find Trials by Condition in Portland

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Study of AZD0120 in Autoimmune Diseases

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Siplizumab in T1DM

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Amplatzer Amulet LAAO vs. NOAC

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

A Study of Navenibart in Participants With Hereditary Angioedema

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19